Revenue
2020
2021
2022
2023
2024
2025
Immuneering Corp (IMRX)
Price$4.82Cached quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $316,952 | $2.1M | $2.3M |
| Gross profit | — | — | $0 | $158,830 | $926,888 | $1.0M |
| Gross margin | — | — | — | 50.11% | 44.56% | 44.61% |
| Research & development | $42.0M | $48.0M | $41.6M | $36.3M | $26.5M | $15.0M |
| Operating expenses | $59.4M | $64.1M | $58.4M | $51.9M | $34.8M | $18.1M |
| Operating income | −$59.4M | −$64.1M | −$58.4M | −$51.7M | −$33.9M | −$17.1M |
| Operating margin | — | — | — | −16,325.77% | −1,629.17% | −739.01% |
| EBITDA | −$59.1M | −$63.7M | −$58.1M | −$51.5M | −$33.8M | −$17.1M |
| EBITDA margin | — | — | — | −16,238.30% | −1,626.98% | −737.96% |
| Net income | −$56.0M | −$61.0M | −$53.5M | −$50.5M | −$33.5M | −$17.0M |
| Net profit margin | — | — | — | −15,937.29% | −1,612.33% | −737.17% |
| Basic EPSper basic share | -$1.27 | -$2.04 | -$1.88 | -$1.91 | -$2.46 | -$3.44 |
| Diluted EPSper diluted share | -$1.27 | -$2.04 | -$1.88 | -$1.91 | -$2.46 | -$3.44 |
Owners
Reported shareholders
15.00%of listed shares
FMR LLC9.7M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FMR LLC | 15.00%9.7M shares |
BlackRock, Inc. | 6.76%4.37M shares |
Zeskind Benjamin J. | ≈4.96%3.21M shares |
Sanofi | 4.19%2.71M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.53%2.29M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 2.99%1.94M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.12%1.37M shares |
Feinberg Peter | ≈1.79%1.16M shares |
STATE STREET CORP | 1.55%1M shares |
DCF Advisers, LLC | 1.22%790K shares |
MARSHALL WACE, LLP | 1.13%731.9K shares |
Connor, Clark & Lunn Investment Management Ltd. | 0.93%601.26K shares |
ALETHEA CAPITAL MANAGEMENT, LLC | 0.73%472.94K shares |
Summit Financial, LLC | 0.70%452.26K shares |
UBS Group AG | 0.69%448.86K shares |
Nuveen, LLC | 0.68%438.36K shares |
NORTHERN TRUST CORP | 0.68%436.99K shares |
LEVIN CAPITAL STRATEGIES, L.P. | 0.64%414K shares |
CITADEL ADVISORS LLC | 0.60%386.41K shares |
Hall Brett Matthew | ≈0.59%382.53K shares |
Percentages use 64.7M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 23, 2026Form 4 | Zeskind Benjamin J.PRESIDENT AND CEO | BuyClass A Common Stock | 2.4K | $4.56 | $10.9K | 2.32M |
| Jun 15, 2026Form 4 | Hall Brett MatthewCHIEF SCIENTIFIC OFFICER | BuyClass A Common Stock | 6.0K | $4.15 | $25.0K | 382.5K |
| Jan 16, 2026Form 4 | Brakewood Harold EugeneChief Business Officer | BuyClass A Common Stock | 5.3K | $4.76 | $25.0K | 11.1K |
| Jan 15, 2026Form 4 | Schall Thomas J.Director | BuyClass A Common Stock | 21.6K | $4.67 | $101.1K | 74.5K |
| Jan 15, 2026Form 4 | Hall Brett MatthewCHIEF SCIENTIFIC OFFICER | BuyClass A Common Stock | 2.3K | $4.57 | $10.5K | 376.5K |